ATOS Atossa Therapeutics Inc
Price (delayed)
$0.651
Market cap
$84.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.2
Enterprise value
$12.9M
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
Highlights
The company's EPS rose by 17% YoY and by 9% QoQ
The net income has grown by 15% YoY and by 5% from the previous quarter
The quick ratio has declined by 15% year-on-year but it has grown by 11% since the previous quarter
The company's equity fell by 21% YoY and by 3% QoQ
Key stats
What are the main financial stats of ATOS
Market
Valuations
Earnings
Shares outstanding
129.17M
Market cap
$84.09M
Enterprise value
$12.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$27.62M
Net income
-$25.5M
EBIT
-$25.5M
EBITDA
-$25.49M
Free cash flow
-$21.05M
Per share
Balance sheet
Liquidity
EPS
-$0.2
EPS diluted
-$0.2
Free cash flow per share
-$0.17
Book value per share
$0.57
Revenue per share
$0
TBVPS
$0.61
Total assets
$76.44M
Total liabilities
$4.97M
Debt
$0
Equity
$71.48M
Working capital
$69.49M
Debt to equity
0
Current ratio
14.99
Quick ratio
14.33
Net debt/EBITDA
2.79
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.6%
Return on equity
-32.8%
Return on invested capital
-7,829.3%
Return on capital employed
-35.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATOS stock price
How has the Atossa Therapeutics stock price performed over time
Intraday
-3.25%
1 week
-10.06%
1 month
-14.98%
1 year
-67.45%
YTD
-31.05%
QTD
-3.25%
Financial performance
How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.62M
Net income
-$25.5M
Gross margin
N/A
Net margin
N/A
The net income has grown by 15% YoY and by 5% from the previous quarter
The operating income rose by 12% YoY and by 6% QoQ
Growth
What is Atossa Therapeutics's growth rate over time
Valuation
What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 17% YoY and by 9% QoQ
ATOS's P/B is 46% below its last 4 quarters average of 2.2 and 41% below its 5-year quarterly average of 2.0
The company's equity fell by 21% YoY and by 3% QoQ
Efficiency
How efficient is Atossa Therapeutics business performance
ATOS's return on invested capital has dropped by 152% since the previous quarter
The return on equity has declined by 11% year-on-year
The ROA has decreased by 7% YoY
Dividends
What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATOS.
Financial health
How did Atossa Therapeutics financials performed over time
The company's total assets fell by 21% YoY and by 3.8% QoQ
The quick ratio has declined by 15% year-on-year but it has grown by 11% since the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity fell by 21% YoY and by 3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.